Hematopoietic stem cell transplantation in patients infected with HIV

Current HIV/AIDS Reports

Volumn 7, Issue 3, 2010, Pages 175-184

  Serrano, David ^a   Miralles, Pilar ^a   Balsalobre, Pascual ^a   Díez Martin, José Luis ^a   Berenguer, Juan ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

AIDS related; Antiretroviral therapy; B cell; Hematopoietic stem cell transplantation; Highly active; HIV infection; Hodgkin's disease; Lymphoma; Transplantation conditioning

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; COTRIMOXAZOLE; CYCLOSPORIN; CYTARABINE; ENFUVIRTIDE; ETOPOSIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MARAVIROC; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; QUINOLONE DERIVATIVE; RALTEGRAVIR; RAPAMYCIN; TACROLIMUS; ZIDOVUDINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; CD4+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; EVENT FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RELAPSE; REVIEW; STEM CELL MOBILIZATION; CASE REPORT; COMPLICATION; HIV INFECTIONS; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; PROCEDURES; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 77955981692     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-010-0050-8     Document Type: Review

References (51)

1. Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA: AIDS-related cancer and severity of immunosuppression in persons with AIDS.J Natl Cancer Inst 2007, 99:962-972.
2. Clifford GM, Rickenbach M, Lise M, et al.: Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009, 113:5737-5742.
3. Pantanowitz L, Dezube BJ: Evolving spectrum and incidence of non-AIDS-defining malignancies. Curr Opin HIV AIDS 2009, 4:27-34.
4. Silverberg MJ, Abrams DI: AIDS-defining and non-AIDSdefining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol 2007, 19:446-451.
5. Kaplan LD, Straus DJ, Testa MA, et al.: Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection.National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997, 336:1641-1648.
6. Knowles DM, Chamulak GA, Subar M, et al.: Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS).The New York University Medical Center experience with 105 patients (1981-1986). Ann Intern Med 1988, 108:744-753.
7. Rubio R: Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative Study Group of Malignancies Associated with HIV Infection of Madrid. Cancer 1994, 73:2400-2407.
8. Berenguer J, Miralles P, Ribera JM, et al.: Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 47:422-428.
9. Miralles P, Berenguer J, Ribera JM, et al.: Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumorrelated factors. J Acquir Immune Defic Syndr 2007, 44:167-173.
10. Ribera JM, Navarro JT, Oriol A, et al.: Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. AIDS 2002, 16:1973-1976.
11. Miralles P, Berenguer J, Ribera Santasusana JM, et al.: GESIDA/ PETHEMA guidelines for the diagnosis and treatment of lymphomas in HIV-infected patients. Med Clin (Barc) 2008, 130:300-311.
12. Philip T, Armitage JO, Spitzer G, et al.: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or highgrade non-Hodgkin's lymphoma. N Engl J Med 1987, 316:1493-1498.
13. Linch DC, Winfield D, Goldstone AH, et al.: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341:1051-1054.
14. Milpied N, Deconinck E, Gaillard F, et al.: Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004, 350:1287-1295.
15. Gabarre J, Marcelin AG, Azar N, et al.: High-dose therapy plus autologous hematopoietic stem cell transplantation for humanimmunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 2004, 89:1100-1108.
16. Krishnan A, Molina A, Zaia J, et al.: Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005,105:874-878.
17. Re A, Michieli M, Casari S, et al.: High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009,114:1306-1313. This is a cooperative study in patients with refractory or relapsed NHL and HL who underwent auto-HSCT, with long-term results and analysis of prognostic factors.
18. Serrano D, Carrion R, Balsalobre P, et al.: HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol 2005, 33:487-494.
19. Serrano D, Miralles P, Carrion R, et al.: Long term follow-up of autologous stem cell transplant in AIDS related lymphoma patients.Results of Spanish cooperative registry GELTAMO/GESIDA [abstract 822]. In 36th Annual Meeting of the European Group for Blood and Marrow Transplantation. Vienna, Austria; 2010.
20. Weichold FF, Zella D, Barabitskaja O, et al.: Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects mostprimitive human hematopoietic stem cells as assessed in longterm bone marrow cultures. Blood 1998, 91:907-915.
21. Koka PS, Jamieson BD, Brooks DG, Zack JA: Human immunodeficiency virus type 1-induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J Virol 1999, 73:9089-9097.
22. Huang SS, Barbour JD, Deeks SG, et al.: Reversal of human immunodeficiency virus type 1-associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis 2000, 30:504-510.
23. Isgro A, Mezzaroma I, Aiuti A, et al.: Recovery of hematopoietic activity in bone marrow from human immunodeficiency virus type 1-infected patients during highly active antiretroviral therapy.AIDS Res Hum Retroviruses 2000, 16:1471-1479.
24. Schooley RT, Mladenovic J, Sevin A, et al.: Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis 2000, 181:148-157.
25. Slobod KS, Bennett TA, Freiden PJ, et al.: Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults. Blood 1996, 88:3329-3335.
26. Diez-Martin JL, Balsalobre P, Re A, et al.: Comparable survival between HIV+and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 2009, 113:6011-6014. This is the first comparative analysis between HIV-infected patients and a matched cohort of non-HIV-infected patients who underwent auto-HSCT for treatment of NHL and HL. Incidence of relapse, OS, and progression-free survival were similar in both cohorts.
27. Krishnan A: Stem cell transplantation in HIV-infected patients.Curr Opin HIV AIDS 2009, 4:11-15.
28. Patrignani N, Anguita J, Pérez Corral A, et al.: Retrospective study of mobilization results in autologous stem cell transplantation in HIV related lymphoma [abstract 521]. In XVII Congress of International Society of Blood Transfusion. Madrid, Spain; 2007.
29. Spitzer TR, Ambinder RF, Lee JY, et al.: Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant 2008, 14:59-66.
30. Department of Health and Human Services: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.December 1, 2009; 1-161. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed March 26, 2010.
31. Balsalobre P, Diez-Martin JL, Re A, et al.: Autologous stemcell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009, 27:2192-2198. This is the report of the European Group for Blood and Marrow Transplantation experience on HIVinfected patients with NHL or HL undergoing auto-HSCT.Multivariate analysis showed that the probability of relapse was higher in patients in non-complete remission before transplantation, in those with histological patterns other than diffuse large Bcell NHL, and in those patients with more than two lines of chemotherapy before transplantation.
32. Krishnan A, Zaia J, Alvarnas J, et al.: HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for B cell non-Hodgkin lymphoma (NHL). ASH Annual Meeting Abstracts 2008, 2181.
33. Krishnan AY, Zaia JA, Rossi JJ, et al.: Autologous stem cell transplantation (ASCT) for AIDS-related lymphomas (ARL) and the potential role of HIV-resistant stem cells. ASH Annual Meeting Abstracts 2006, 491.
34. Dezube BJ, Aboulafia DM, Pantanowitz L: Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma. AIDS Read 2004, 14:372-374, 377-379.
35. Aboulafia DM, Meneses M, Ginsberg S, et al.: Acute myeloid leukemia in patients infected with HIV-1. AIDS 2002, 16:865-876.
36. Schlaberg R, Fisher JG, Flamm MJ, et al.: Chronic myeloid leukemia and HIV-infection. Leuk Lymphoma 2008, 49:1155-1160.
37. Qiu J, Terasaki PI, Waki K, et al.: HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006, 81:1658-1661.
38. Tateo M, Roque-Afonso AM, Antonini TM, et al.: Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009, 23:1069-1076.
39. Gupta V, Tomblyn M, Pedersen TL, et al.: Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research.Biol Blood Marrow Transplant 2009, 15:864-871. This is a report from the Center for International Blood and Marrow Transplant Research database of 23 HIV-positive patients undergoing allo- HSCT between 1987 and 2003. The results suggest that the procedure is feasible for selected HIV-positive patients with malignant and nonmalignant disorders.
40. Binaghi MA, Lasala MB, Longoni H, et al.: Peripheral blood stem cell transplantation in a patient with acquired aplastic anemia and HIV infection. ASH Annual Meeting Abstracts 2006, 5368.
41. Bryant A, Milliken S: Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma.Biol Blood Marrow Transplant 2008, 14:601-602.
42. Hutter G, Nowak D, Mossner M, et al.: Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009, 360:692-698.
43. Kang EM, de Witte M, Malech H, et al.: Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome.Blood 2002, 99:698-701.
44. Polizzotto MN, Skinner M, Cole-Sinclair MF, et al.: Allo-SCT for hematological malignancies in the setting of HIV. Bone Marrow Transplant 2010, 45:584-586.
45. Schlegel P, Beatty P, Halvorsen R, McCune J: Successful allogeneic bone marrow transplant in an HIV-1-positive man with chronic myelogenous leukemia. J Acquir Immune Defic Syndr 2000, 24:289-290.
46. Serrano D, Carrion R, Miralles P, et al.: Allogeneic hematopoietic stem cell transplantation in HIV-positive patients with high risk hematologic malignancies. Blood 2008,112:abstract 4387.
47. Sora F, Antinori A, Piccirillo N, et al.: Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia. Exp Hematol 2002, 30:279-284.
48. Tomonari A, Takahashi S, Shimohakamada Y, et al.: Unrelated cord blood transplantation for a human immunodeficiency virus- 1-seropositive patient with acute lymphoblastic leukemia. Bone Marrow Transplant 2005, 36:261-262.
49. Wolf T, Rickerts V, Staszewski S, et al.: First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe aplastic anemia. Haematologica 2007, 92:e56-e58.
50. Woolfrey AE, Malhotra U, Harrington RD, et al.: Generation of HIV-1-specific CD8+ cell responses following allogeneic hematopoietic cell transplantation. Blood 2008, 112:3484-3487.
51. Hutter G, Allers K, Schneider T: The additional use of viral entry inhibitors during autologous hematopoietic stem cell transplantation in patients with non-Hodgkin s lymphoma and HIV-1 infection. Biol Blood Marrow Transplant 2009 Nov 2 (Epub ahead of print).